February 15, 2015 / by / News
SolAeroMed managment and clinicians are attending, presenting SolAeroMed technology at the following conferences in 2015. Respiratory Drug Delivery, Antibes, Francis: May 5-8 2015 (unconfirmed) American Thoracic Society, Denver: May 15-20, 2015 (confirmed) BIO2015, Philadelphia: June 15-18, 2015 (unconfirmed) European Respiratory Society, Amsterdam: Sept 26-30, 2015 (confirmed) Respiratory Drug Delivery, Phoenix: April 17-21 2016 (confirmed)
Read more
SolAeroMed is promoting a new S1226 Phase II trial in Cystic Fibrosis
June 16, 2019 / by / News
March 15, 2019 A Scientific Poster was presented at a University of Calgary event in Q1 2019
Read more
S1226 Portable Delivery Advanced Design Concept
June 27, 2018 / by / News
We have now completed a $150,000 grant with Calgary based SAIT, which build on the earlier work by Melbourne based Hydrix. The result is a more advanced design for our portable S1226 delivery device.
Read more
Treatment of Acute Asthma in the ICU
June 26, 2018 / by / News
In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead clinician ‘shockingly good’. This case study was presented in May at the American Thoracic Society meeting in San Diego. Full presentation available in poster form.
Read more
SolAeroMed Investment Announcement
December 6, 2016 / by / News
CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.
Read more
SolAeroMed Announces Positive Proof-of-Concept Data for Its Lead Drug (S-1226) in Subjects with Mild Atopic Asthma
May 30, 2016 / by / News
CALGARY, Alberta, May 30, 2016 – SolAeroMed Inc. (“SolAeroMed”), a Calgary-based biotechnology company dedicated to developing novel drugs and devices to treat respiratory diseases, today announced positive Phase IIa proof-of-concept results for its S-1226 lead therapeutic. The Phase IIa study was a placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%)
Read more
SolAeroMed Announces Completion of Phase IIA Proof of Concept Recruitment for S-1226
November 24, 2015 / by / News
CALGARY, Alberta, November 24, 2015 – SolAeroMed Inc., dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases, today announced its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology by late Fall 2015. “We are very pleased the clinical trial site
Read more
European Respiratory Society Conference
September 23, 2015 / by / News
SolAeroMed Inc will be attending the European Thoracic Society conference in Amsterdam, Netherlands to present their S-1226 drug and device technologies. Abstract for S-1226 Drug: We have discovered a new short acting bronchodilator represents a new class of bronchodilator. The drug, S-1226, is made up of a gas (4-12% CO2 in air) combined with a synthetic
Read more
American Thoracic Society Conference
June 1, 2015 / by / News
SolAeroMed management and clinicians attended the American Thoracic Society in Denver, Colorado to present an overview of their current technologies, with a focus on the lead S-1226 drug. The abstract for the presentation can be accessed at: http://www.atsjournals.org/doi. The poster is available here: ATS 2015 Poster
Read more
Investment and partnering
March 2, 2015 / by / News
Dr John Dennis, CEO Background SolAeroMed Inc.’s (“SAMi”) drug candidate S-1226 has been under development by the company’s scientific founders since the early 1990s. Their work into the mechanisms underlying a surge in the western Canadian provinces of asthma-related deaths led to the discovery of a novel therapeutic intervention. Patent applications were filed in December
Read more
Conference networking 2015
February 15, 2015 / by / News
SolAeroMed managment and clinicians are attending, presenting SolAeroMed technology at the following conferences in 2015. Respiratory Drug Delivery, Antibes, Francis: May 5-8 2015 (unconfirmed) American Thoracic Society, Denver: May 15-20, 2015 (confirmed) BIO2015, Philadelphia: June 15-18, 2015 (unconfirmed) European Respiratory Society, Amsterdam: Sept 26-30, 2015 (confirmed) Respiratory Drug Delivery, Phoenix: April 17-21 2016 (confirmed)
Read more